-- 周一上午晚些时候，欧洲股市在美国交易，美国存托凭证（ADR）本周开盘走势平稳，标普欧洲精选ADR指数小幅上涨0.02%，至1822.16点。 欧洲大陆方面，生物制药公司Cellectis (CLLS)和电信公司诺基亚(NOK)领涨，分别上涨26%和9.3%。紧随其后的是家具制造商Natuzzi (NTZ)和生物技术公司Evaxion (EVAX)，分别上涨7.1%和3.4%。 欧洲大陆方面，住宿预订公司trivago (TRVG)和啤酒公司百威英博(BUD)领跌，分别下跌3.3%和1.2%。紧随其后的是制药公司赛诺菲(SNY)和银行桑坦德银行(SAN)，分别下跌0.9%和0.8%。 英国股市涨幅居前的股票包括制药公司Silence Therapeutics (SLN)和生物制药公司Mereo BioPharma Group (MREO)，分别上涨7%和4.8%。紧随其后的是生物制药公司NuCana (NCNA)和Bicycle Therapeutics (BCYC)，分别上涨4.1%和2.4%。 英国和爱尔兰股市跌幅居前的股票包括生物技术公司Trinity Biotech (TRIB)和邮轮运营商Carnival (CUK)，分别下跌4.7%和3.3%。紧随其后的是生物制药公司Biodexa Pharmaceuticals (BDRX)和巴克莱银行(BCS)，分别下跌2.2%和0.9%。
Related Articles
Asia
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
$KOSDAQ:440110
Asia
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.
$BOM:524715$NSE:SUNPHARMA